PetVivo HoldingsPETV -0.12%31 Net Current Asset Value is $0.01 as of Mar. 2026, which is 100% below its 10-year median of 29.99. GuruFocus rates PETV with a GF Score™ of 31/100 and a GF Value™ of $0.51 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 568 Medical Devices & Instruments companies, PetVivo Holdings ranks worse than 96.48% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
PetVivo Holdings's net current asset value per share for the quarter that ended in Mar. 2026 was $0.01.
The historical rank and industry rank for PetVivo Holdings's Net Current Asset Value or its related term are showing as below:
PETV'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.85 Med: 29.99 Max: 83.9
Current: 83.9
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of PetVivo Holdings was 83.90. The lowest was 3.85. And the median was 29.99.
PETV's Price-to-Net-Current-Asset-Value is ranked worse than 96.48% of 568
companies
in the Medical Devices & Instruments industry
Industry Median: 5.1
vs PETV: 83.90
PetVivo Holdings (OTCPK:PETV) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
PetVivo Holdings Net Current Asset Value Related Terms
PetVivo Holdings Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for PetVivo Holdings's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PETV vs ARAY, RDGL, NSPR: Net Current Asset Value Comparison
For the Medical Devices subindustry, PetVivo Holdings's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PetVivo Holdings Price-to-Net-Current-Asset-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PetVivo Holdings's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where PetVivo Holdings's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $0.01 mean?
PetVivo Holdings (PETV) has a Net Current Asset Value of $0.01 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on PetVivo Holdings and its competitors. This is 100% below median its historical median of 29.99. Over the past decade, PetVivo Holdings' Net Current Asset Value has ranged from 3.85 to 83.90. According to the industry distribution chart, PetVivo Holdings ranks #548 out of 568 companies in the Medical Devices & Instruments industry, placing it in the top 96.5%.
Is PetVivo Holdings' Net Current Asset Value too high?
PetVivo Holdings' current Net Current Asset Value of $0.01 is 100% below median its 10-year median of 29.99. Over the past 10 years, this metric has ranged from a low of 3.85 to a high of 83.90. The Medical Devices & Instruments industry median Net Current Asset Value is 5.10. PetVivo Holdings' value of $0.01 is 99.8% below this industry median. Based on the distribution chart, PetVivo Holdings ranks #548 out of 568 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, PetVivo Holdings has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PetVivo Holdings' Net Current Asset Value compare to ARAY and RDGL?
According to the Medical Devices & Instruments industry distribution chart, PetVivo Holdings ranks #548 out of 568 companies for Net Current Asset Value. This places PetVivo Holdings in the lower half of its industry. The industry median Net Current Asset Value is 5.10. PetVivo Holdings' value of $0.01 is 99.8% below this benchmark. Historically, PetVivo Holdings' own Net Current Asset Value has ranged from 3.85 to 83.90 over the past decade. While the company's 10-year median is 29.99 vs. the industry median of 5.10, PetVivo Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Devices & Instruments company?
The median Net Current Asset Value among Medical Devices & Instruments companies is 5.10, based on 568 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PetVivo Holdings's current Net Current Asset Value of $0.01 is 99.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on PetVivo Holdings and its competitors. For the Medical Devices & Instruments industry, the median Net Current Asset Value is 5.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PetVivo Holdings's current Net Current Asset Value is $0.01, which is 100% below median its own 10-year median of 29.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PetVivo Holdings stock overvalued right now?
Based on GuruFocus' analysis, PetVivo Holdings (PETV) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.51, compared to a current price of $0.84 — trading 64.5% above its estimated fair value. The current Net Current Asset Value is $0.01, which is 100% below median its 10-year median of 29.99 and 99.8% below the Medical Devices & Instruments industry median of 5.10. PetVivo Holdings' overall GF Score™ is 31/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For PetVivo Holdings (PETV), the current Net Current Asset Value is $0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PetVivo Holdings (PETV) Overvalued in 2026?
Based on GuruFocus' analysis, PetVivo Holdings stock appears to be overvalued.
The current stock price of $0.84 is trading 64.5% above its estimated GF Value™ of $0.51.
GuruFocus considers PetVivo Holdings to be Significantly Overvalued.
Key valuation signals for PETV:
Net Current Asset Value: $0.01 (100% below median its 10-year median of 29.99)
GF Value™: $0.51 vs. price of $0.84 (64.5% above fair value)
Industry Position: 99.8% below the Medical Devices & Instruments median (#548 of 568)
No single metric tells the full story. See the PETV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PetVivo Holdings Inc is an emerging biomedical device company. It is focused on the manufacturing, commercialization, and licensing of medical devices and therapeutics for companion animals. The product pipeline includes approximately seventeen products intended to treat animals and people. Its patent protection extends to biomaterials, products, production processes, and methods of use provided by the company's portfolio of several patents. The company has also begun the commercialization of its product Spryng with OsteoCushion technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions such as osteoarthritis in dogs and horses.
31GF Score
Get the complete analysis for PETV
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PETV has been successfully added to your 
